Drug Type Small molecule drug |
Synonyms Andante, Bunazosin, Bunazosin hydrochloride (JP17) + [10] |
Target |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (16 Apr 1985), |
Regulation- |
Molecular FormulaC19H28ClN5O3 |
InChIKeyNBGBEUITCPENLJ-UHFFFAOYSA-N |
CAS Registry52712-76-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01887 | Bunazosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | JP | 20 Jun 2001 | |
Heart Failure | JP | 28 Feb 1995 | |
Essential Hypertension | JP | 16 Apr 1985 | |
Hypertension, Renal | JP | 16 Apr 1985 |
Not Applicable | - | - | Topical 0.01% bunazosin hydorochloride | clqiywqypl(yboommldwy) = decreased significantly gcjfmxhgbt (lxglgztgwc ) | - | 01 May 2004 | |
Not Applicable | - | - | ankatrlcuf(cyekjjskas) = ohtpftcqxg momnqkriql (gllytsymoe ) | Positive | 01 May 2003 |